Antifungal activity against Candida species of the selective serotonin-reuptake inhibitor, sertraline.
case_report · Level V
Where this comes from
- Record sourced from PubMed, PMID 11700578.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Three patients with premenstrual dysphoric disorder (PMDD) and recurrent vulvovaginal candidiasis (VVC) underwent sertraline therapy (Tresleen, a selective serotonin-reuptake inhibitor; Pfizer) for PMDD. During sertraline intervention, patients had no recurrent episodes of acute VVC. Antifungal activity was observed for sertraline against various isolates of Candida species.
Medical subject headings
- Antifungal Agents
- Candida
- Candidiasis, Vulvovaginal
- Premenstrual Syndrome
- Selective Serotonin Reuptake Inhibitors
- Sertraline